Patents by Inventor Chu-Biao Xue

Chu-Biao Xue has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic sulfone derivatives as inhibitors of matrix metalloproteinases and/or TNF-Alpha converting enzyme (TACE)
    Publication number: 20030149031
    Abstract: The present application describes novel cyclic sulfone derivatives of formula I: 1
    Type: Application
    Filed: October 7, 2002
    Publication date: August 7, 2003
    Inventors: Jingwu Duan, Chu-Biao Xue
  • Novel Cyclic hydroxamic acid as metalloproteinase inhibitors
    Publication number: 20030139597
    Abstract: The present application describes novel cyclic hydroxamic acids of formula I: 1
    Type: Application
    Filed: June 20, 2002
    Publication date: July 24, 2003
    Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
  • Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)
    Publication number: 20030130273
    Abstract: The present application describes novel hydantoin derivatives of formula (I): 1
    Type: Application
    Filed: May 23, 2002
    Publication date: July 10, 2003
    Inventors: James E. Sheppeck, Jingwu Duan, Chu-Biao Xue, Zelda Wasserman
  • 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20030087890
    Abstract: The present application describes novel 1,2-disubsituted cyclic derivatives of formula I: 1
    Type: Application
    Filed: January 9, 2002
    Publication date: May 8, 2003
    Inventors: Chu-Biao Xue, Carl Decicco, Xiaohua He
  • Novel amide derivatives as inhibitors of matrix metalloproteinases, TNF-alpha, and aggrecanase
    Publication number: 20030032803
    Abstract: The present application describes novel amides and derivatives thereof of formula 1
    Type: Application
    Filed: February 12, 2002
    Publication date: February 13, 2003
    Inventors: Jingwu Duan, Carl P. Decicco, David J. Nelson, Chu-Biao Xue
  • 1,1-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20020137734
    Abstract: The present application describes novel 1,1-disubsituted cyclic derivatives of formula I: 1
    Type: Application
    Filed: January 9, 2002
    Publication date: September 26, 2002
    Inventors: Xiao-Tao Chen, Chu-Biao Xue
  • Cyclic hydroxamic acids as metalloproteinase inhibitors
    Patent number: 6429213
    Abstract: The present application de gibes novel cyclic hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring B is a 5-7 membered cyclic system containing from 0-2 heteroatoms selected from O, N, NRa, and S(O)p, and 0-1 carbonyl groups and the other variables are defined in the present specification, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: June 17, 1999
    Date of Patent: August 6, 2002
    Inventors: Chu-Biao Xue, Carl P. Decicco, Xiaohua He
  • Amide derivatives as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase
    Patent number: 6376665
    Abstract: The present application describes novel amides and derivatives thereof of formula I: or pharmaceutically acceptable salt forms thereof, wherein these compounds are useful as inhibitors of matrix metalloproteinases, TNF-&agr;, and aggrecanase.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: April 23, 2002
    Inventors: Jingwu Duan, Carl P. Decicco, David J. Nelson, Chu-Biao Xue
  • Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
    Publication number: 20020016336
    Abstract: The present application describes novel cyclic &bgr;-amino acid derivatives of formula I: 1
    Type: Application
    Filed: March 16, 2001
    Publication date: February 7, 2002
    Inventors: Jingwu Duan, Gregory R. Ott, Lihua Chen, Carl Decicco, Zhonghui Lu, Thomas P. Maduskuie, Matthew E. Voss, Chu-Biao Xue
  • Substituted aryl hydroxamic acids as metalloproteinase inhibitors
    Patent number: 6268379
    Abstract: The present application describes novel substituted aryl hydroxamic acids of formula I: or pharmaceutically acceptable salt forms thereof, wherein ring A is a 5-8 membered ring containing from 0-2 heteroatoms selected from N, 0, and S, which are useful as metalloprotease inhibitors.
    Type: Grant
    Filed: May 13, 1999
    Date of Patent: July 31, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Chu-Biao Xue, Carl P. Decicco, Ruth R. Wexler
  • Isoxazoline and isoxazole fibrogen receptor antagonists
    Patent number: 6114328
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: September 5, 2000
    Assignee: Dupont Pharmaceuticals Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Isoxazoline and isoxazole fibrinogen receptor antagonists
    Patent number: 5849736
    Abstract: This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: December 15, 1998
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John Wityak, Chu-Biao Xue, Thais Motria Sielecki-Dzurdz, Richard Eric Olson, William Frank Degrado, Gary Avonn Cain, Douglas Guy Batt, Donald Pinto, Munir Alwan Hussain, Shaker Ahmed Mousa
  • Hydroxamic acid compounds as metalloprotease and TNF inhibitors
    Patent number: 5703092
    Abstract: The present invention provides novel hydroxamic acids and carbocyclic acids and derivatives thereof and to pharmaceutical compositions and methods of use of these novel compounds for the inhibition of matrixmetalloproteinases, such as stromelysin and other matrix metalloproteinases, and also inhibit the production of tumor necrosis factor (TNF), and are therefore useful for the treatment of arthritis and other related inflammatory diseases.
    Type: Grant
    Filed: April 16, 1996
    Date of Patent: December 30, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Chu-Biao Xue, William F. DeGrado, Carl Peter DeCicco, Irina Cipora Jacobson
  • Compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
    Patent number: 5691329
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: November 25, 1997
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: William Frank DeGrado, Chu-Biao Xue
  • Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
    Patent number: 5563158
    Abstract: This invention relates to novel compounds containing basic and acidic termini, pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: November 22, 1994
    Date of Patent: October 8, 1996
    Assignee: The Dupont Merck Pharmaceutical Company
    Inventors: William F. DeGrado, Chu-Biao Xue